The Donors Advisory Committee (DAC) advises DCVMN on donor-funded activities and has no executive role. As a strictly advisory, non-governing body, the DAC does not have either decision-making authority or fiduciary responsibilities. It is composed by three DCVMN members and four external advisers from FVMRH/Imperial College London, PATH, BMGF and NIIMBL, who are supporting and guiding the Network on principles, technical and scientific activities for member manufacturers, e.g. training programs. Members are appointed by the Executive Committee according to advice and support requirements. DCVMN-CEO is the ex-officio member of DAC. Appointment duration is dependent on the Advisory Committee needs and individual availability.
Biovac Institute, South Africa
Mr. Tippoo has been with Biovac since its inception in 2003, serving as Head of Science & Innovation, The Biovac Institute. He heads product and business development and is responsible for fostering strategic alliances as well as local and international partnering opportunities with respect to product development and inbound and outbound technology transfer projects.
Mr. Azhari joined Biofarma in 1989 and has vast experience in biotechnology, Quality Management including Good Manufacturing Practices. He is a pharmacist and holds a Master’s degree in Operations Management. He is currently a member of the Board of Executives of Biofarma as Senior Executive Vice President overseeing Research and Development activities. His previous appointments in the company were Head of Business Planning and Strategy, Head of Quality Assurance/responsible pharmacist, Head of bacterial vaccines production and Head of formulation/filling/packaging.
Jong Ho Park
LG Chem, South Korea
Mr. Jongho Park is Director of the Overseas Sales Department in LG Chem. He joined the business support team of LG Chem in 1995. After 10 years of experience in developing and implementing a sales force effectiveness program for the domestic market, he moved to the overseas business team, becoming team leader in 2011. He then moved to the vaccine sales team as team leader in 2016, specializing in vaccines. After the Vaccine Business Division merged with the Specialty Drug Business Division, and he was promoted to Director of the Overseas Sales Department, in 2019, responsible for the leadership and overall management of overseas sales for vaccines, fertility treatment drugs, diagnostics and veterinary products. Mr Park has a Bachelor’s degree from Sungkyunkwan University in Korea, majoring in Genetic Engineering.
Dr. David Kaslow
Dr. Kaslow is Vice President for Essential Medicines at PATH, which includes the Drug Development Program and the PATH Center for Vaccine Innovation and Access (CVIA). Before joining PATH in 2012, he held key advisory positions with PATH’s Malaria Vaccine Initiative (MVI) and the Bill & Melinda Gates Foundation. Dr. Kaslow previously worked at Merck, Vical and NIAID in research and product development roles. He studied biochemistry at University of California, Davis, and medicine at University of California, San Francisco.
Bill & Melinda Gates Foundation, USA
Mr. Prasad is Senior CMC Advisor in Vaccine Development, Global Health. Before joining The Foundation, Mr. Prasad was COO and President, Vaccines & Biologics at Biological E and a board member for Qualivax, a GSK-BE joint venture. Mr. Prasad’s 40 years of experience include senior roles at Genentech, Chiron Novartis, Medimmune and Genzyme.
Prof. Robin Shattock
Professor Shattock is Head of Mucosal Infection and Immunity, Department of Medicine, Imperial College, London. His research focuses on the mechanisms of mucosal infection and the development of novel preventative strategies appropriate to a developing world setting. He oversees a portfolio of research that is supported by 26 members of staff and has published over 160 peer reviewed articles in this area.
Dr Benjamin Pierce
Future Vaccine Manufacturing Hub, Imperial College, London
Dr. Pierce is Operations Manager for the Future Vaccine Manufacturing Research Hub, Imperial College London, directed by Prof Robin Shattock. The FVMR Hub is committed towards researching innovative and more cost-effective vaccines for populations in developing countries and includes 8 leading UK-based institutes as well as grantees laboratories in Vietnam), India, Uganda, China and Bangladesh. Dr Pierce holds a PhD in Chemistry from University of North Carolina.
Prof. Kelvin H. Lee
Kelvin H. Lee is Gore Professor of Chemical and Biomolecular Engineering at the University of Delaware and is Director of NIIMBL: the National Institute for Innovation in Manufacturing Biopharmaceuticals, one of 16 Manufacturing USA Institutes. He received a BSE in Chemical Engineering from Princeton and PhD in Chemical Engineering from Caltech. He spent several years in the Biotechnology Institute at the ETH in Zurich, Switzerland and also completed a postdoc in Caltech’s Biology Division.
Dr. Sonia Pagliusi
Executive Secretary (non-voting)
Dr. Pagliusi is the Executive Secretary of DCVMN International since 2011 and is deeply committed to improving healthcare globally. She has over 25 years of professional experience, with a balanced track record in both private and public sectors, working with leading multinational pharmaceutical and biotechnology industries, in research and development and with WHO in vaccine quality assessment and introduction. She holds degrees in Biomedical Sciences from Paulista Medical School, Brazil, Biochemistry Diploma from Free University Berlin, a PhD in Molecular Biology from Heidelberg University and a Public Health Management degree from Geneva University.